Mantle Cell Lymphoma is a rare form of blood cancer that starts in the lymph nodes, which are small glands that help the body fight infection. Some patients have already received a type of immune therapy called CAR T-cell therapy, where a person’s own immune cells are changed in a lab to attack the cancer, but the disease can still come back or not improve enough. This study will give an experimental medicine named glofitamab directly into a vein (intravenous use). The treatment may be given in low or higher doses and will be combined with two other medicines, obinutuzumab and tocilizumab, which are also given by IV infusion.
The purpose of the study is to evaluate how well glofitamab works in people whose disease has returned or did not respond well after CAR T-cell therapy. Participants will receive a series of IV infusions over several months, with regular doctor visits and imaging scans to check whether the cancer shrinks or disappears. Terms such as “response” mean a measurable reduction in tumor size, and “complete response” means no detectable cancer remains on the scans. The study will follow each participant for about a year to see how long any benefit lasts and to monitor any side effects.
Italy 
